Pharmacy Times May 25, 2023
Ashley Gallagher, Associate Editor

It is Celltrion’s first biosimilar and the second anti-TNFα biosimilar approved for use in the US.

The FDA has approvedadalimumab-aaty (Yuflyma; Celltrion USA), a high concentration and citrate-free formulation of adalimumab (Humira; Abbvie) biosimilar.

The 100 mg/mL strength was approved for the treatment of 8 conditions: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

“[Adalimumab-aaty] offers patients a high-concentration and citrate-free formulation of adalimumab biosimilar, providing an alternative treatment option for patients. It represents a key treatment option in patient care and patient choice,” Tom Nusbickel, chief commercial officer at Celltrion USA, said in a press release.

Adalimumab-aaty is Celltrion’s first biosimilar and the second anti-tumor necrosis...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
What New Gene Therapy Means For Sickle Cell Patients
Inside this year’s ASCO: Biggest data drops, trends and the best exhibit booth
2024 Pharm Exec Top 50 Companies
Federal Support Should Not Be A Factor In Determining Pharmaceutical Prices Under The IRA
Chutes & Ladders—Longtime J&J exec retiring after 17 years

Share This Article